{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:30:30Z","timestamp":1771475430932,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159302"],"award-info":[{"award-number":["92159302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022ZDZX001"],"award-info":[{"award-number":["2022ZDZX001"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"project for disciplines of excellence, West China Hospital, Sichuan University","award":["ZYGD22009"],"award-info":[{"award-number":["ZYGD22009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84108-6","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:49:32Z","timestamp":1735872572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma"],"prefix":"10.1038","volume":"15","author":[{"given":"Haoyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84108_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/JTO.0b013e31819f2e0e","volume":"4","author":"HC Roberts","year":"2009","unstructured":"Roberts, H. C. et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J. Thorac. Oncol. 4, 620\u2013628. https:\/\/doi.org\/10.1097\/JTO.0b013e31819f2e0e (2009).","journal-title":"J. Thorac. Oncol."},{"key":"84108_CR2","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.1073\/pnas.1105887108","volume":"108","author":"M Carbone","year":"2011","unstructured":"Carbone, M. et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc. Natl. Acad. Sci. USA. 108, 13618\u201313623. https:\/\/doi.org\/10.1073\/pnas.1105887108 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"84108_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.22526","volume":"109","author":"MJ Teta","year":"2007","unstructured":"Teta, M. J., Lau, E., Sceurman, B. K. & Wagner, M. E. Therapeutic radiation for lymphoma: Risk of malignant mesothelioma. Cancer 109, 1432\u20131438. https:\/\/doi.org\/10.1002\/cncr.22526 (2007).","journal-title":"Cancer"},{"key":"84108_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"84108_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","volume":"7","author":"VW Rusch","year":"2012","unstructured":"Rusch, V. W. et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J. Thorac. Oncol. 7, 1631\u20131639. https:\/\/doi.org\/10.1097\/JTO.0b013e31826915f1 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"84108_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","volume":"25","author":"AC Bibby","year":"2016","unstructured":"Bibby, A. C. et al. Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment. Eur. Respir Rev. 25, 472\u2013486. https:\/\/doi.org\/10.1183\/16000617.0063-2016 (2016).","journal-title":"Eur. Respir Rev."},{"key":"84108_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","volume":"17","author":"JL Sauter","year":"2022","unstructured":"Sauter, J. L. et al. The 2021 WHO classification of tumors of the Pleura: advances since the 2015 classification. J. Thorac. Oncol. 17, 608\u2013622. https:\/\/doi.org\/10.1016\/j.jtho.2021.12.014 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"84108_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","volume":"196","author":"RR Meyerhoff","year":"2015","unstructured":"Meyerhoff, R. R. et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J. Surg. Res. 196, 23\u201332. https:\/\/doi.org\/10.1016\/j.jss.2015.01.043 (2015).","journal-title":"J. Surg. Res."},{"key":"84108_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","volume":"88","author":"P Beckett","year":"2015","unstructured":"Beckett, P. et al. Demographics, management and survival of patients with malignant pleural mesothelioma in the national lung cancer audit in England and Wales. Lung Cancer. 88, 344\u2013348. https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.005 (2015).","journal-title":"Lung Cancer"},{"key":"84108_CR10","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2012.5535","volume":"307","author":"HE Davies","year":"2012","unstructured":"Davies, H. E. et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. Jama 307, 2383\u20132389. https:\/\/doi.org\/10.1001\/jama.2012.5535 (2012).","journal-title":"Jama"},{"key":"84108_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2020.05.032","volume":"146","author":"AB Thompson","year":"2020","unstructured":"Thompson, A. B. et al. Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A surveillance, epidemiology, and end results (SEER) study. Lung Cancer. 146, 120\u2013126. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.032 (2020).","journal-title":"Lung Cancer"},{"key":"84108_CR12","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano, M. T. & Zhang, H. Malignant pleural mesothelioma: A population-based study of survival. J. Thorac. Oncol. 5, 1841\u20131848. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f1cf2b (2010).","journal-title":"J. Thorac. Oncol."},{"key":"84108_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/s2213-2600(24)00111-5","volume":"12","author":"KG Blyth","year":"2024","unstructured":"Blyth, K. G. et al. Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respir Med. 12, 476\u2013483. https:\/\/doi.org\/10.1016\/s2213-2600(24)00111-5 (2024).","journal-title":"Lancet Respir Med."},{"key":"84108_CR14","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/cts.13260","volume":"15","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis. Clin. Transl Sci. 15, 1340\u20131354. https:\/\/doi.org\/10.1111\/cts.13260 (2022).","journal-title":"Clin. Transl Sci."},{"key":"84108_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000321370","volume":"80","author":"AC Tanrikulu","year":"2010","unstructured":"Tanrikulu, A. C. et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration 80, 480\u2013487. https:\/\/doi.org\/10.1159\/000321370 (2010).","journal-title":"Respiration"},{"key":"84108_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.chest.2021.05.063","volume":"160","author":"R Asciak","year":"2021","unstructured":"Asciak, R. et al. The Association between pleural fluid exposure and survival in pleural mesothelioma. Chest 160, 1925\u20131933. https:\/\/doi.org\/10.1016\/j.chest.2021.05.063 (2021).","journal-title":"Chest"},{"key":"84108_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.001","volume":"116","author":"J Paajanen","year":"2018","unstructured":"Paajanen, J. et al. Computed tomography in the evaluation of malignant pleural mesothelioma-association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival. Lung Cancer. 116, 73\u201379. https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.001 (2018).","journal-title":"Lung Cancer"},{"key":"84108_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1513\/AnnalsATS.201811-786OC","volume":"16","author":"AC Bibby","year":"2019","unstructured":"Bibby, A. C. et al. The prevalence and clinical relevance of Nonexpandable Lung in malignant pleural mesothelioma. A prospective, single-center cohort study of 229 patients. Ann. Am. Thorac. Soc. 16, 1273\u20131279. https:\/\/doi.org\/10.1513\/AnnalsATS.201811-786OC (2019).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"84108_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/resp.12874","volume":"22","author":"HM Cheah","year":"2017","unstructured":"Cheah, H. M. et al. Malignant pleural fluid from mesothelioma has potent biological activities. Respirology 22, 192\u2013199. https:\/\/doi.org\/10.1111\/resp.12874 (2017).","journal-title":"Respirology"},{"key":"84108_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/jco.21.01567","volume":"40","author":"AS Tsao","year":"2022","unstructured":"Tsao, A. S., Pass, H. I., Rimner, A. & Mansfield, A. S. New era for malignant pleural mesothelioma: Updates on therapeutic options. J. Clin. Oncol. 40, 681\u2013692. https:\/\/doi.org\/10.1200\/jco.21.01567 (2022).","journal-title":"J. Clin. Oncol."},{"key":"84108_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 33, 488\u2013499. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074 (2022).","journal-title":"Ann. Oncol."},{"key":"84108_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/s1470-2045(23)00446-1","volume":"24","author":"LH Douma","year":"2023","unstructured":"Douma, L. H. et al. Pembrolizumab plus Lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): A single-arm phase 2 study. Lancet Oncol. 24, 1219\u20131228. https:\/\/doi.org\/10.1016\/s1470-2045(23)00446-1 (2023).","journal-title":"Lancet Oncol."},{"key":"84108_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtho.2023.08.004","volume":"19","author":"M Tagliamento","year":"2024","unstructured":"Tagliamento, M. et al. Meta-analysis on the combination of Chemotherapy with programmed death-ligand 1 and programmed cell death protein 1 blockade as first-line treatment for unresectable pleural mesothelioma. J. Thorac. Oncol. 19, 166\u2013172. https:\/\/doi.org\/10.1016\/j.jtho.2023.08.004 (2024).","journal-title":"J. Thorac. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84108-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T23:04:09Z","timestamp":1735945449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84108-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84108"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84108-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}